Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vicki G Davis

Showing results (11-20 of 23) with videos related to

Pageof 3
Sort By:
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|July 13, 2020
The 2018 Banff Working Group classification of definitive polyomavirus nephropathy: A multicenter validation study in the modern eraVolker Nickeleit, Harsharan K Singh, Darshana Dadhania, et al.
Schizophrenia Research|August 11, 2014
Circadian rhythms in cognitive functioning among patients with schizophrenia: impact on signal detection in clinical trials of potential pro-cognitive therapiesMichael R Hufford, Vicki G Davis, Dana Hilt, et al.
Journal of Visualized Experiments : Jove|May 7, 2014
Development of a virtual reality assessment of everyday living skillsStacy A Ruse, Vicki G Davis, Alexandra S Atkins, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|July 17, 2014
Reliability, validity and treatment sensitivity of the Schizophrenia Cognition Rating ScaleRichard S E Keefe, Vicki G Davis, Nathan B Spagnola, et al.
JAMA Psychiatry|June 22, 2017
Placebo Response and Practice Effects in Schizophrenia Cognition TrialsRichard S E Keefe, Vicki G Davis, Philip D Harvey, et al.
The American Journal of Psychiatry|December 11, 2024
The Impact of Xanomeline and Trospium Chloride on Cognitive Impairment in Acute Schizophrenia: Replication in Pooled Data From Two Phase 3 TrialsWilliam P Horan, Colin Sauder, Philip D Harvey, et al.
Schizophrenia Research|April 24, 2017
Psychometric characteristics of the MATRICS Consensus Cognitive Battery in a large pooled cohort of stable schizophrenia patientsAnastasia Georgiades, Vicki G Davis, Alexandra S Atkins, et al.
Biological Psychiatry|July 31, 2009
Inflammatory markers in schizophrenia: comparing antipsychotic effects in phase 1 of the clinical antipsychotic trials of intervention effectiveness studyJonathan M Meyer, Joseph P McEvoy, Vicki G Davis, et al.
Schizophrenia Research|June 7, 2008
Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE Schizophrenia Trial phase 1Jonathan M Meyer, Vicki G Davis, Joseph P McEvoy, et al.
Schizophrenia Research|September 9, 2008
Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia studyGail L Daumit, Donald C Goff, Jonathan M Meyer, et al.
Pageof 3

Showing results (11-20 of 23) with videos related to

Sort By:
Pageof 3
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|July 13, 2020
The 2018 Banff Working Group classification of definitive polyomavirus nephropathy: A multicenter validation study in the modern eraVolker Nickeleit, Harsharan K Singh, Darshana Dadhania, et al.
Schizophrenia Research|August 11, 2014
Circadian rhythms in cognitive functioning among patients with schizophrenia: impact on signal detection in clinical trials of potential pro-cognitive therapiesMichael R Hufford, Vicki G Davis, Dana Hilt, et al.
Journal of Visualized Experiments : Jove|May 7, 2014
Development of a virtual reality assessment of everyday living skillsStacy A Ruse, Vicki G Davis, Alexandra S Atkins, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|July 17, 2014
Reliability, validity and treatment sensitivity of the Schizophrenia Cognition Rating ScaleRichard S E Keefe, Vicki G Davis, Nathan B Spagnola, et al.
JAMA Psychiatry|June 22, 2017
Placebo Response and Practice Effects in Schizophrenia Cognition TrialsRichard S E Keefe, Vicki G Davis, Philip D Harvey, et al.
The American Journal of Psychiatry|December 11, 2024
The Impact of Xanomeline and Trospium Chloride on Cognitive Impairment in Acute Schizophrenia: Replication in Pooled Data From Two Phase 3 TrialsWilliam P Horan, Colin Sauder, Philip D Harvey, et al.
Schizophrenia Research|April 24, 2017
Psychometric characteristics of the MATRICS Consensus Cognitive Battery in a large pooled cohort of stable schizophrenia patientsAnastasia Georgiades, Vicki G Davis, Alexandra S Atkins, et al.
Biological Psychiatry|July 31, 2009
Inflammatory markers in schizophrenia: comparing antipsychotic effects in phase 1 of the clinical antipsychotic trials of intervention effectiveness studyJonathan M Meyer, Joseph P McEvoy, Vicki G Davis, et al.
Schizophrenia Research|June 7, 2008
Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE Schizophrenia Trial phase 1Jonathan M Meyer, Vicki G Davis, Joseph P McEvoy, et al.
Schizophrenia Research|September 9, 2008
Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia studyGail L Daumit, Donald C Goff, Jonathan M Meyer, et al.
Pageof 3